In the Spotlight...
There are no spotlights this week
Previous Digests
Step aside, DC1s, there’s a new sheriff in town
November 24, 2021
While conventional type 1 DCs (DC1s) are recognized as key drivers of CD8+ T cell antitumor immunity, a variety of antigen-presenting cell (APC) subsets reside within the tumor microenvironment, and their roles remain incompletely understood. Recently reported in Immunity...
Myeloid cells provide CD28 costimulation that’s key to overcoming TIL exhaustion
November 17, 2021
Immune checkpoint blockade is a powerful treatment for many cancers, and a number of factors are known to predict or contribute to responses. However, some cancers that seem set up for success, like high-grade serous epithelial ovarian cancer (HGSOC)...
New dysfunctional TIL family limits checkpoint responses in lung cancer
November 10, 2021
Many non-small cell lung cancer (NSCLC) tumors do not respond to immune checkpoint blockade (ICB), even in the presence of CD8+ tumor-infiltrating lymphocytes (TILs). To explore the mechanisms behind this phenomenon, Horton et al. evaluated T cell phenotypes and...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
Donate to support researchersAbout ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ed Fritsch
Ute Burkhardt
Lauren Hitchings
Gaelle Lespinasse-Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Samuel (Sandy) Goldman
Paula Hochman
Shishir Pant
Elaine Yee Lin Chung
Nathan Suek
Margot O'Toole
Taylor Lord
TESTIMONIALS
I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.
Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT
